Pricing Log in Create free account
Friday 6 November 2026 Export CGON’s income statement to Excel — free account

CG Oncology, Inc.

CGON Healthcare Biotechnology

CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.

Revenue
−3.72%
EPS
−12.3%
Free cash flow
−25.2%
Total debt
0.00%

Quarter to September 2026, against a year earlier

76.08 11.28 +17.41%
Market cap
$5.7B
P/E
0.0×
Fwd P/E
−19.5×
Dividend yield
—
F-score
2/9
Altman Z
49.04
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

CG Oncology, Inc. (CGON) Net income

Alert me on Net income

CG Oncology, Inc.'s net income for fiscal 2025 was −$161.0M, compared with −$88.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$237.5M. Net income has fallen for 3 consecutive fiscal years. CG Oncology, Inc. ranks 534th of 605 Biotechnology companies by net income.

Net income, annual

Embed this chart

Annual newest first

Period Net income Change
FY2025 −$161.0M —
FY2024 −$88.0M —
FY2023 −$48.6M —
FY2022 −$35.4M —

Quarterly newest first

Period Net income Change
Sep 2026 −$56.9M —
Jun 2026 −$79.1M —
Mar 2026 −$60.2M —
Dec 2025 −$41.3M —
12 more quarters

Net income against peers

Company Net income
LGND Ligand Pharmaceuticals Incorporated compare $51.5M
BLTE Belite Bio, Inc. Sponsored ADR compare −$77.6M
PTCT PTC Therapeutics, Inc. compare −$106.0M
MANE Veradermics Incorporated compare −$136.4M
CGON CG Oncology, Inc. −$224.4M
KOD Kodiak Sciences Inc. compare −$242.0M
SRRK Scholar Rock Holding Corporation compare −$408.6M
IMVT Immunovant, Inc. compare −$538.2M
MIRM Mirum Pharmaceuticals, Inc. compare −$903.9M

What Net income is

Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.

Reported line item

The full definition of Net income →

More on CGON